Open Access
Med Buccale Chir Buccale
Volume 19, Number 1, janvier 2013
Page(s) 11 - 19
Section Mises au point / Literature reviews
Published online 20 November 2012
  1. Haas S, Schellong S. New anticoagulants: from bench to bedside. Hamostaseologie 2007;27:41-7. [PubMed] [Google Scholar]
  2. SFMBCB. Recommandations pour la prise en charge des patients sous traitement anti-vitamines K en chirurgie bucco-dentaire. Méd buccale Chir buccale 2006;12:188-92. [Google Scholar]
  3. Levi MM, Eerenberg E, Lowenberg E, Kamphuisen PW. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med 2010;68:68-76. [PubMed] [Google Scholar]
  4. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009;15:244-52. [PubMed] [Google Scholar]
  5. Albaladejo P. Synthèse et perspectives (Rivaroxaban). Ann Fr Anesth Rea 2008;27Suppl3:S28-31. [Google Scholar]
  6. Strebel N, Prins M, Agnelli G, Buller HR. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 2002;162:1451-6. [CrossRef] [PubMed] [Google Scholar]
  7. Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008;99:208-14. [PubMed] [Google Scholar]
  8. Turpie AG, Eriksson BI, Lassen MR, Bauer KA. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. J South Orthop Assoc 2002;11:182-8. [PubMed] [Google Scholar]
  9. McRae SJ, Ginsberg JS. The diagnostic evaluation of deep vein thrombosis. Am Heart Hosp J 2004;2:205-10. [CrossRef] [PubMed] [Google Scholar]
  10. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. Br Med J 2006;332:325-9. [CrossRef] [PubMed] [Google Scholar]
  11. Wienbergen H, Zeymer U. Management of acute coronary syndromes with fondaparinux. Vasc Health Risk Manag 2007;3:321-9. Epub 2007/08/21. [PubMed] [Google Scholar]
  12. Weitz JI. New oral anticoagulants in development. Thromb Haemost 2010;103:62-70. [CrossRef] [PubMed] [Google Scholar]
  13. HAS. Commission de transparence. Rivaroxaban 2009. [Google Scholar]
  14. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140:867-73. [CrossRef] [PubMed] [Google Scholar]
  15. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010;159:340-7. [Google Scholar]
  16. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374:29-38. [CrossRef] [PubMed] [Google Scholar]
  17. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56. [CrossRef] [PubMed] [Google Scholar]
  18. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New Eng J Med 2009;361:2342-52. [CrossRef] [PubMed] [Google Scholar]
  19. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009;157:805-10. [CrossRef] [PubMed] [Google Scholar]
  20. Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008;111:4871-9. [CrossRef] [PubMed] [Google Scholar]
  21. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-40. [CrossRef] [PubMed] [Google Scholar]
  22. Samama CM. Thromboprophylaxie perioperatoire : brève revue et recommandations. Ann Fr Anesth Rea 2008;27Suppl3:S2-8. [CrossRef] [Google Scholar]
  23. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303. [CrossRef] [PubMed] [Google Scholar]
  24. Phillips KW, Ansell J. The clinical implications of new oral anticoagulants: will the potential advantages be achieved? Thromb Haemost 2010;103:34-9. [CrossRef] [PubMed] [Google Scholar]
  25. Harder S. Renal profiles of anticoagulants. J Clin Pharmacol 2012;52:964-75. [CrossRef] [PubMed] [Google Scholar]
  26. Perzborn E, Kubitza D, Misselwitz F. Rivaroxaban - A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. Hamostaseologie 2007;27:282-9. [PubMed] [Google Scholar]
  27. Huvers F, Slappendel R, Benraad B, van Hellemondt G, van Kraaij M. Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. Neth J Med 2005;63:184-6. [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.